Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5,555,556
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
483,800
-
Shares change
-
-15,305
-
Total reported value, excl. options
-
$1,345,652
-
Value change
-
-$46,888
-
Number of buys
-
5
-
Number of sells
-
-6
-
Price
-
$2.78
Significant Holders of Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) as of Q4 2023
21 filings reported holding LPCN - Lipocine Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 483,800 shares
of 5,555,556 outstanding shares and own 8.71% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (221,459 shares), BlackRock Inc. (74,846 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (56,601 shares), GEODE CAPITAL MANAGEMENT, LLC (48,854 shares), TWO SIGMA ADVISERS, LP (26,222 shares), RENAISSANCE TECHNOLOGIES LLC (18,797 shares), STATE STREET CORP (18,626 shares), WEALTH EFFECTS LLC (14,639 shares), Tower Research Capital LLC (TRC) (2,238 shares), and MORGAN STANLEY (722 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.